Global Somatostatin Market Growth 2025-2031

The global Somatostatin market size is predicted to grow from US$ 408 million in 2025 to US$ 798 million in 2031; it is expected to grow at a CAGR of 11.8% from 2025 to 2031.

Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.

Global Somatostatin key players include Merck (Schweiz) AG, SANOFI-AVENTIS FRANCE, Lyomark Pharma GmbH, ALFA WASSERMANN S.p.A., HYBIO, etc. Global top five manufacturers hold a share over 65%.

China is the largest market, followed by Europe and India.

LP Information, Inc. (LPI) ' newest research report, the “Somatostatin Industry Forecast” looks at past sales and reviews total world Somatostatin sales in 2024, providing a comprehensive analysis by region and market sector of projected Somatostatin sales for 2025 through 2031. With Somatostatin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Somatostatin industry.

This Insight Report provides a comprehensive analysis of the global Somatostatin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Somatostatin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Somatostatin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Somatostatin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Somatostatin.

This report presents a comprehensive overview, market shares, and growth opportunities of Somatostatin market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

0.25mg/pcs

0.75mg/pcs

3mg/pcs

Segmentation by Application:

Hormonal Disorder

Oncology

Metabolic Disorder

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Merck (Schweiz) AG

SANOFI-AVENTIS FRANCE

Lyomark Pharma GmbH

ALFA WASSERMANN S.p.A.

Polypeptide Laboratories, Inc

SAMARTH

UBPL

HYBIO

TianTaiShan

Yangtze River

Siyao

Shuangcheng

Hainan Zhonghe

SL PHARM

Wuhan Hualong

Qingdao Guoda

Chengdu Shengnuo

Longjin

Key Questions Addressed in this Report

What is the 10-year outlook for the global Somatostatin market?

What factors are driving Somatostatin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Somatostatin market opportunities vary by end market size?

How does Somatostatin break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.